Retinal Drug Toxicity: When Systemic Drugs Poison the Retina

Why the retina is uniquely vulnerable

High metabolism, no regeneration, and a pigment layer that loves to hoard. The photoreceptors and their support layer, the retinal pigment epithelium (RPE), are among the most metabolically active tissues in the body — and, being neural, they do not regenerate once lost. Two features make them a magnet for drug toxicity. First, the RPE is rich in melanin, and melanin binds many drugs avidly; a molecule can lodge in the pigment and be released slowly over months and years, so tissue levels far outlast the last dose. Second, the retina lives behind a blood–retinal barrier that concentrates certain compounds. Put these together and you get the defining feature of retinal drug toxicity: it is usually dose- and duration-dependent, cumulative, and slow to appear — and, because melanin keeps releasing the drug, it can keep progressing even after the drug is stopped.

Hydroxychloroquine: the exam classic

The single most important drug on this page, and the reason screening programmes exist. Hydroxychloroquine (Plaquenil) and its older cousin chloroquine are antimalarials repurposed as disease-modifying anti-rheumatic drugs. They are workhorses of rheumatology — first-line for systemic lupus erythematosus and widely used in rheumatoid arthritis — which is exactly why they cross paths with so many patients. This links directly to the Inflammation & Joints / Rheumatology chapters, where the same drug is prized for controlling disease; the ocular monitoring is the price of that long-term use. The retinal toxicity concentrates the drug in the RPE of the macula and, over years, kills the photoreceptors around the fovea in a ring, sparing the very centre at first. The result is the classic "bull's-eye maculopathy": a doughnut of damage encircling a preserved centre.

The danger is that early toxicity is silent. Central acuity — the number on the letter chart — stays normal until damage is advanced, because the fovea is spared last. By the time the patient notices a blur, irreversible photoreceptor loss has already happened, and it may progress even after stopping. So the whole discipline is built around catching the paracentral ring before the patient can feel it. Modern screening uses tests far more sensitive than acuity: automated visual fields (looking for a paracentral scotoma, classically on a 10-2 field), spectral-domain OCT (showing early thinning and the "flying saucer" loss of the outer retina around the fovea), and fundus autofluorescence (which lights up the stressed RPE as a ring). A baseline eye exam is done within the first year of starting the drug, and regular screening begins after about five years — sooner if extra risk factors are present.

The risk factors are the exam's favourite detail — and they drive prescribing. Toxicity is driven above all by daily dose relative to body size and by total duration of use. Modern guidance doses hydroxychloroquine by ideal (lean) body weight — keeping the daily dose at or below roughly 5 mg/kg of real weight sharply lowers risk — because dosing by actual weight in an overweight patient overshoots the retina's tolerance. Cumulative years matter enormously: risk climbs steeply after five years and after a large cumulative dose. Renal impairment raises risk, because the kidney clears the drug, so a failing kidney lets levels build. Concurrent tamoxifen and pre-existing macular disease add further risk. Notice how this is a genuine drug-monitoring programme, not a one-off warning: right dose by lean weight, watch the kidneys, count the years, and screen with the sensitive tests before the patient can feel anything.

Thioridazine and the phenothiazines: pigmentary retinopathy

Thioridazine, an older antipsychotic of the phenothiazine class, is the second classic retinal toxin. At high doses it causes a pigmentary retinopathy: the RPE clumps and mottles, and patients report blurred vision, dyschromatopsia (colour disturbance), and difficulty seeing at night. Unlike hydroxychloroquine's tidy paracentral ring, thioridazine produces coarse pigment clumping across the mid-periphery and posterior pole, and severe cases can progress to widespread RPE atrophy. Chlorpromazine, another phenothiazine, more often deposits in the lens and cornea than the retina, but the lesson is the same: high-dose, long-term phenothiazines can poison the pigmented layers of the eye, so exceeding the dose ceiling for thioridazine is the thing to avoid. This connects to the Psychopharmacology material, where antipsychotic adverse-effect profiles are compared class by class.

The wider gallery: tamoxifen, interferon, oncology drugs, poppers

Once you know the pattern, you start recognising it under many drug names. Tamoxifen, the anti-oestrogen used in breast cancer, can deposit tiny refractile crystals in the inner retina — a crystalline retinopathy — and, less often, a cystoid maculopathy that blurs central vision; it is classically dose-related and links to the Oncology chapters (and, as above, compounds hydroxychloroquine's risk). Interferon, used for hepatitis and some cancers, causes interferon retinopathy — cotton-wool spots and small haemorrhages from a microvascular insult, usually reversible on stopping. Modern oncology has added its own signatures: the MEK inhibitors (for example trametinib) cause a distinctive serous retinal detachment/retinopathy that is typically reversible, while the checkpoint inhibitors covered in the Oncology immunotherapy chapter can trigger immune-mediated ocular inflammation such as uveitis (a MEK-inhibitor and checkpoint story that belongs beside the irAEs). Two odder causes round out the list: "poppers" (inhaled isobutyl/alkyl nitrites, used recreationally) cause a foveal maculopathy with a yellowish central spot, and canthaxanthin, an oral tanning and food-colour pigment, deposits as glistening crystals in a ring around the macula.

The unifying lessons

Stand back and the same principles recur — the principles the Toxicology chapter teaches for any drug-induced organ injury. First, most retinal drug toxicity is dose- and duration-dependent: it is the cumulative exposure, not a single tablet, that does the harm, so the prescriber's arithmetic (dose per body weight, years of use, renal clearance) is protective medicine. Second, some of these injuries need formal screening programmes — hydroxychloroquine above all — because the damage is silent until it is permanent. Third, reversibility splits the list in two: interferon and MEK-inhibitor retinopathy often recover when the drug stops, whereas hydroxychloroquine and thioridazine damage is largely irreversible and can even progress. And fourth, tying it all together: a careful drug history is the single most useful test in unexplained visual loss. The bottle in the patient's bathroom cabinet may be the diagnosis.